Status
Conditions
Treatments
About
The purpose of this study is to compare outcomes when patients with degenerative sacroiliitis (arthritis of the SI joint) and or sacroiliac disruption (abnormal separation or tearing of the sacroiliac joint)undergo either SI joint fusion with the iFuse Implant System or undergo specific, targeted non-surgical treatment of the SI joint.
Full description
The intended analysis was to examine differences in responses at 6 months. It was acknowledged that subjects with chronic pain in the NSM arm group might not experience any benefit as there was little evidence at the time that NSM was helpful. The protocol included optional crossover to other treatments, including surgical treatment. The protocol anticipated a high crossover rate and therefore did not include any comparative analyses after month 6.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age 21-70 at time of screening
Patient has lower back pain for >6 months inadequately responsive to conservative care
Diagnosis of sacroiliac joint disruption or degenerative sacroiliitis based on ALL of the following:
i. SI joint disruption:
ii. Degenerative sacroiliitis:
Baseline Oswestry Disability Index (ODI) score of at least 30%
Baseline SI joint pain score of at least 50 on 0-100 mm visual analog scale*
Patient has signed study-specific informed consent form
Patient has the necessary mental capacity to participate and is physically able to comply with study protocol requirements
Exclusion criteria
Severe back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, and lumbar vertebral body fracture**
Other known sacroiliac pathology such as:
History of recent (<1 year) major trauma to pelvis
Previously diagnosed osteoporosis (defined as prior T-score <-2.5 or history of osteoporotic fracture). Patients meeting the osteoporosis screening criteria identified by the National Osteoporosis Foundation should be screened for osteoporosis with DEXA.**** See Section 3.6.4.
Osteomalacia or other metabolic bone disease
Chronic rheumatologic condition (e.g., rheumatoid arthritis)
Any condition or anatomy that makes treatment with the iFuse Implant System infeasible
Chondropathy
Known allergy to titanium or titanium alloys
Use of medications known to have detrimental effects on bone quality and soft-tissue healing
Prominent neurologic condition that would interfere with physical therapy
Current local or systemic infection that raises the risk of surgery
Patient currently receiving or seeking worker's compensation, disability remuneration, and/or involved in injury litigation.
Currently pregnant or planning pregnancy in the next 2 years
Patient is a prisoner or a ward of the state.
Known or suspected drug or alcohol abuse***
Diagnosed psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation
Patient is participating in an investigational study or has been involved in an investigational study within 3 months prior to evaluation for participation
Primary purpose
Allocation
Interventional model
Masking
159 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal